Stock Traders Buy Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading on Wednesday. Traders purchased 1,002 put options on the stock. This represents an increase of approximately 1,791% compared to the typical daily volume of 53 put options.

Insiders Place Their Bets

In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $5.03, for a total value of $125,750.00. Following the transaction, the general counsel now directly owns 167,618 shares of the company’s stock, valued at $843,118.54. This trade represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.63% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC increased its position in Maravai LifeSciences by 7.3% during the fourth quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock worth $180,000 after buying an additional 2,239 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Maravai LifeSciences by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company’s stock valued at $164,000 after acquiring an additional 2,851 shares during the last quarter. Performa Ltd US LLC raised its stake in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after acquiring an additional 4,300 shares in the last quarter. FNY Investment Advisers LLC lifted its holdings in Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Orion Portfolio Solutions LLC lifted its holdings in Maravai LifeSciences by 4.8% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 135,749 shares of the company’s stock worth $1,128,000 after purchasing an additional 6,177 shares during the last quarter. Institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

Shares of MRVI opened at $2.21 on Thursday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74. The firm has a market cap of $562.08 million, a PE ratio of -1.35 and a beta of -0.08. The firm’s 50 day moving average price is $3.55 and its 200 day moving average price is $5.45. Maravai LifeSciences has a twelve month low of $2.07 and a twelve month high of $11.56.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Bank of America lowered their price objective on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, March 3rd. UBS Group lowered their price target on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a report on Friday, March 21st. Guggenheim assumed coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating for the company. Stifel Nicolaus set a $5.00 target price on Maravai LifeSciences in a research note on Friday, March 21st. Finally, Morgan Stanley reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Hold” and an average target price of $7.31.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.